Tirzepatide
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 252
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Part A: Bimagrumab Dose 2 + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Part A: Bimagrumab Placebo + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Dose 1 + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Part B: Bimagrumab Placebo + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
Not shown
- Part A: Bimagrumab Dose 2 + Tirzepatide Placebo: endpoint not reported
- Part A: Bimagrumab Placebo + Tirzepatide Dose 1: endpoint not reported
- Part A: Bimagrumab Placebo + Tirzepatide Dose 2: endpoint not reported
- Part A: Bimagrumab Dose 1 + Tirzepatide Dose 1: endpoint not reported
- Part A: Bimagrumab Dose 1 + Tirzepatide Dose 2: endpoint not reported
- Part A: Bimagrumab Dose 2 + Tirzepatide Dose 2: endpoint not reported
- Part A: Bimagrumab Placebo + Tirzepatide Placebo: endpoint not reported
- Part B: Bimagrumab Dose 2 (no titration) + Tirzepatide Dose 1: endpoint not reported
- Part B: Bimagrumab Dose 2 (fast titration) + Tirzepatide Dose 1: endpoint not reported
- Part B: Bimagrumab Dose 2 (slow titration) + Tirzepatide Dose 1: endpoint not reported
- Part B: Bimagrumab Dose 1 + Tirzepatide Placebo: endpoint not reported
- Part B: Bimagrumab Placebo + Tirzepatide Placebo: endpoint not reported